M
Marguerite L. Monogue
Researcher at University of Texas Southwestern Medical Center
Publications - 37
Citations - 2726
Marguerite L. Monogue is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Medicine & Cefepime. The author has an hindex of 13, co-authored 31 publications receiving 2167 citations. Previous affiliations of Marguerite L. Monogue include Hartford Hospital.
Papers
More filters
Journal ArticleDOI
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
TL;DR: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918 and both the need and capability to produce high-quality evidence even in the middle of a pandemic.
Journal ArticleDOI
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
TL;DR: Data derived in the current study will assist with the delineation of MIC susceptibility breakpoints for cefiderocol against these important nosocomial Gram-negative pathogens; however, additional clinical data are required to substantiate these observations.
Journal ArticleDOI
Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
TL;DR: The pharmacokinetics, pharmacodynamics and 24-h efficacy of cefiderocol is described using dose-ranging methods in a neutropenic murine thigh infection model and targets for stasis and 1 log10 and 2 log10 reductions ranged from 44.4-94.7, 50.2-97.5 and 62.1-100, respectively.
Journal ArticleDOI
In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model.
Marguerite L. Monogue,Lilian M. Abbo,Rossana Rosa,Jose F. Camargo,Octavio Martinez,Robert A. Bonomo,Robert A. Bonomo,David P. Nicolau +7 more
TL;DR: In vivo synergy with ceftazidime-avibactam and aztreonam against an MDR Klebsiella pneumoniae harboring NDM was observed but no in vivo synergy was observed in vitro.
Journal ArticleDOI
In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.
TL;DR: The data support the potential clinical utility of meropenem-nacubactam for cUTI in humans against MDR Enterobacteriaceae, although further clinical data supporting mer Openem- nacUBactam efficacy are needed.